Myriad Genetics , Inc. (NASDAQ:MYGN) stock has reached a new 52-week low, touching down at $12.16, as the company faces a challenging market environment. According to InvestingPro data, technical ...

However, the tone changed in 2001 when Myriad sent cease-and-desist letters to Ontario Government laboratories to stop BRCA testing. This triggered an overwhelming negative political and media ...

Commitment to innovation : Myriad continues to develop new technologies like molecular residual disease (MRD) assay and bring innovations to existing products. Its Labs of the Future initiative ...

Myriad is acknowledged as one of the first commercial laboratories to market a multi-ancestry breast-cancer PRS, supporting its commitment to health equity and inclusive genetic insights.

As set forth above, the company’s financial results for the quarter and full year ended December 31, 2024 set forth in this press release are preliminary and subject to Myriad Genetics’ normal quarter ...

SALT LAKE CITY, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its Quality, Innovation, and Corporate ...